drug company, which is working on highly-targeted therapies, says Roche will help develop and commercialize the drug camonsertib.for the treatment of tumors.
Repare says under the terms of the licence and collaboration agreement, it will receive a US$125 million upfront payment, and is “eligible to receive up to US$1.2 billion in potential clinical, regulatory, commercial and sales milestones.”
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: